TICKERNERD
Menu
JNJJNJHealthcare · Drug Manufacturers - General

JNJ Stock Forecast: Johnson & Johnson Price Predictions for 2026-2027

Last close, 21 Aug 2026
$270
+1.10% on the day

The 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $280 — +3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$651.3B
Ticker Nerd rank
92 / 100
Median analyst target
$280
Analysts covering
23
Total return, dividends reinvested
1W
+3.8%
1M
+7.9%
YTD
+32.1%
1Y
+54.8%
From 52W high
−1.1%
From 52W low
+57.9%
$171
$273
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JNJ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Quality
95
Momentum
92
Value
88
Issuance
87
Revisions
67
Growth
63
Accruals
47
Size
0

Volatility (100): The share price has been relatively steady.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JNJ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26JNJHigh $305Median $280Low $190

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says23 analysts
16 Buy6 Hold1 Sell
Low $190Median $280High $305

The green dot is the last close — the median target sits +3.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$270 → $287
3 Aug 2026Wells FargoMaintainsOverweight$272 → $282
17 July 2026GuggenheimReiteratesBuy—
17 July 2026GuggenheimReiteratesBuy$270
16 July 2026Morgan StanleyMaintainsOverweight—
16 July 2026Morgan StanleyMaintainsOverweight$284 → $294
16 July 2026Raymond JamesMaintainsOutperform$258 → $265
16 July 2026Raymond JamesMaintainsOutperform—
16 July 2026RBC CapitalReiteratesOutperform$287
16 July 2026RBC CapitalReiteratesOutperform—
16 July 2026Wells FargoMaintainsOverweight$263 → $272
16 July 2026Wells FargoMaintainsOverweight—
13 July 2026RBC CapitalMaintainsOutperform$265 → $287
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026TD CowenMaintainsBuy$250 → $300
13 July 2026TD CowenMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsNeutral—
10 July 2026B of A SecuritiesMaintainsNeutral$254 → $263
8 July 2026CitigroupMaintainsBuy$285 → $298
8 July 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JNJ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

JNJ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.5%
Analysts raising
0
Analysts cutting
4
Fundamentals

Johnson & Johnson (JNJ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.4×

Cheaper than 25% of US stocks

Price / sales
6.7×

Cheaper than 20% of US stocks

Price / book
7.7×

Cheaper than 14% of US stocks

EV / EBITDA
19.5×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
6.6%

Higher than 43% of US stocks

Earnings growth (YoY)
−0.1%

Higher than 35% of US stocks

Gross margin
68.2%

Higher than 81% of US stocks

Operating margin
29.2%

Higher than 86% of US stocks

Net margin
21.5%

Higher than 83% of US stocks

Returns & dividend
Return on equity
25.7%

Higher than 85% of US stocks

Return on assets
8.6%

Higher than 90% of US stocks

Dividend yield
2.0%

Higher than 45% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

JNJ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
JNJJohnson & Johnson$651.3B
92
ABBVAbbVie, Inc.$468.1B
96
MRKMerck & Co., Inc.$378.6B
83
LLYEli Lilly & Co.$1.2T
91
AMGNAmgen, Inc.$236.8B
92
GILDGilead Sciences, Inc.$181.4B
92
PFEPfizer Inc.$159.6B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JNJ news & analysis

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

The Motley Fool · 23 Aug 2026positive

The Motley Fool compares Abbott Laboratories and Johnson & Johnson as dividend kings, noting that while Abbott has faced challenges it should overcome them. Johnson & Johnson is described as performing well with potentially more to come.

Why it matters — The article highlights Johnson & Johnson's strong current performance and potential for further gains, which is relevant for investors monitoring the company's outlook.

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

Seeking Alpha · 23 Aug 2026positive

Johnson & Johnson reported strong second-quarter sales growth driven by its top drugs DARZALEX and TREMFYA and raised its full-year guidance. The company highlighted CAPLYTA's label expansion for schizophrenia relapse prevention and the potential first-mover status of IMAAVY in wAIHA as growth catalysts.

Why it matters — JNJ watchers would care because the company's latest sales results and pipeline milestones point to continued growth drivers across its portfolio.

Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update

Zacks Investment Research · 21 Aug 2026positive

Johnson & Johnson received FDA 510(k) clearance for the MONARCH QUEST 3 update, which adds AI-powered planning, navigation, and imaging upgrades for robotic bronchoscopy.

Why it matters — A JNJ watcher would care because FDA clearance for new AI-enhanced capabilities in its MONARCH robotic bronchoscopy platform could strengthen its medical technology portfolio.

Merck vs. J&J: Which Healthcare Giant Should Investors Choose?

Zacks Investment Research · 21 Aug 2026positive

A Zacks Investment Research article compares Merck and Johnson & Johnson as healthcare investment choices. It states that JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both companies face patent expiration challenges.

Why it matters — JNJ watchers would note that the company's diversification and pipeline are highlighted as strengths relative to a competitor facing similar patent expirations.

Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research · 20 Aug 2026negative

Johnson & Johnson shares closed at $267.37 in the latest trading session, a -2.21% move from the previous day. The company registered a bigger fall than the broader market.

Why it matters — A JNJ watcher would care because the stock's decline in this session outpaced the overall market, reflecting a notable single-day drop in the company's share price.

FAQ

Frequently asked questions about JNJ stock

What is the JNJ stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $280, with estimates ranging from $190 to $305. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JNJ stock a buy right now?

Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 92 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JNJ?

As at 22 Aug 2026, Johnson & Johnson ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will JNJ stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +3.6% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 92 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JNJ stock forecast for 2030?

No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $305 over the next 12 months.

How has JNJ stock performed over the past year?

Johnson & Johnson returned +54.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Johnson & Johnson do?

Johnson & Johnson is a global healthcare company focused on Innovative Medicine and MedTech. The company develops and markets prescription medicines and medical technologies used in areas such as oncology, immunology, neuroscience, cardiovascular care, surgery, orthopedics, and vision care.

What is the latest news on JNJ?

The most recent item we track (The Motley Fool, 23 Aug 2026): "Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?". The Motley Fool compares Abbott Laboratories and Johnson & Johnson as dividend kings, noting that while Abbott has faced challenges it should overcome them. Johnson & Johnson is described as performing well with potentially more to come.

Company

About Johnson & Johnson.

Johnson & Johnson is a global healthcare company focused on Innovative Medicine and MedTech. The company develops and markets prescription medicines and medical technologies used in areas such as oncology, immunology, neuroscience, cardiovascular care, surgery, orthopedics, and vision care. Its portfolio includes treatments for complex diseases, hospital and clinician-focused devices, surgical systems, and vision products that support diagnosis, treatment, and recovery across care settings. Johnson & Johnson serves patients, healthcare professionals, hospitals, and health systems through products designed to make care more precise, less invasive, and more effective. Headquartered in New Brunswick, New Jersey, Johnson & Johnson remains a major force in the healthcare market, combining pharmaceutical research with medical technology to address a broad range of clinical needs.

CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com